SFX by Ex Libris Inc.

Title:	Clinical trials. Halt of Celebrex study threatens drug's future, other trials
Source:	Science [0036-8075] Couzin, J yr:2004

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Couzin, J. "Massive Trial of Celebrex Seeks to Settle Safety Concerns." Science 310.5756 (2005): 1890-1891.
description	2.	anonymous. "Stepping into the Vioxx void. Answers to four questions after the popular pain reliever was yanked off the market." Harvard health letter (2005): 6-.
description	3.	Couzin, J. "Drug testing. Massive trial of Celebrex seeks to settle safety concerns." Science 310.5756 (2005): 1890-1.
description	4.	Ng, A. "Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models." Journal of Alzheimer's disease 6.4 (2004): 367-77.
description	5.	Finkel, Sanford I I. "A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil." International journal of geriatric psychiatry 19.1 (2003): 9-18.
description	6.	Sugao, H. "Renal lymphangioma." The Journal of urology (1999): 484-5.
description	7.	Castgillo, J R. "Combined Chondroitin sulfate and Glucosamine is more efficient than Celebrex in reducing serum levels of COLL2-1, a cartilage degradation biomarker, in patients with severe OA: results from a randomized, double-blind, multicentric clinical trial." Clinical Therapeutics 37.8 (2015).
description	8.	Mullin, R. "Pfizer settles Celebrex suit.(News of the Week)(lawsuit over the cyclooxygenase-2 inhibitor)." Chemical & engineering news 90.19 (2012): 6-.
description	9.	Yelland, M. "Individual medication effectiveness test comparing celecoxib with extended release paracetamol for osteoarthritis." Australasian musculoskeletal medicine 9.1 (2004): 49-.
description	10.	Simon, Lee S S. "The COX 2 selective inhibitors: what the newspapers have not told you." Bulletin of the NYU Hospital for Joint Diseases 65.3 (2007): 229-41.
description	11.	McMorran, M. "Celecoxib (Celebrex): 1 year later." CMAJ 162.7 (2000): 1044-6.
description	12.	Marrer, E. "Impact of biomarker development on drug safety assessment." Toxicology and Applied Pharmacology 243.2 (2010): 167-179.
description	13.	Hinz, B. "More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib." Arthritis and rheumatism 54.1 (2005): 282-291.
description	14.	Hawkey, E. "Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multina." Arthritis and rheumatism 43.2: 370-377.
description	15.	Araújo, C C C. "Biological activities of Curcuma longa L." Memórias do Instituto Oswaldo Cruz 96.5 (2001): 723-8.
description	16.	Polvikoski, T ). "Prevalence of Alzheimer's disease in very elderly people: A prospective neuropathological study." Neurology 56.12 (2001): 1690-1696.
description	17.	Aggarwal, B. "Suppression of the nuclear factor-kappa B activation pathway by spice-derived phytochemicals - Reasoning for seasoning." Annals of the New York Academy of Sciences 1030.1 (2004): 434-441.
description	18.	Curtis, Jeptha P P. "Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study." BMJ 327.7427 (2004): 1322-3.
description	19.	Couzin, J. "Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors." Science 306.5695 (2004): 384-5.
description	20.	Levsky, M E E. "Sertraline-induced hyponatremia in an older patient." Journal of the American Geriatrics Society 46.12 (1999): 1582-3.